Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Prof. Joseph Itskovitz-Eldor, a World Leader in the Field of Stem Cells Joins Kadimastems Board of Directors

Apr. 2, 2018

Ness Ziona, Israel, 2 April 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the appointment of Professor Joseph Itskovitz-Eldor as a director on its Board of Directors. Professor Itskovitz-Eldor, a world leader in the field of stem cells, has been accompanying Kadimastem for the past four years as a member of its Scientific Advisory Board.

Upon the company's advancement to the clinical stage and the commencement of its phase I/IIa clinical trial in ALS patients using the unique cell therapy developed by the company, as announced around two weeks ago, Kadimastem is placing emphasis on expanding its managerial basis by adding a global opinion leader to its board of directors.

Professor Itskovitz-Eldor served as the head of the Obstetrics and Gynecology Department at Rambam Medical Center for 22 years, founded the Technion's embryonic stem cell center and is a professor emeritus at the Technion. In addition, Prof. Itskovitz-Eldor initiated the collaboration with James Thomson, of the University of Wisconsin in Madison, which derived the first human embryonic stem cells worldwide, and later in Israel as well.

In the research laboratories headed by Prof. Itskovitz-Eldor, the derivation of embryonic stem cells from a human source and their differentiation into various cell types was researched. Prof. Itskovitz-Eldor has published more than 200 scientific publications, in fields such as embryonic physiology, fertility medicine and pluripotent embryonic stem cells.

Yossi Ben-Yossef, CEO of Kadimastem, noted: "I believe that Professor Itskovitz-Eldor's substantial experience and achievements will help the company upon its entering the important clinical stage. This step is consistent with the company's vision and establishing its position as a leading, groundbreaking company in the regenerative medicine field."

Professor Itskovitz-Eldor noted: "My joining as a director of Kadimastem’s board advances another stage in a journey that I embarked on twenty years ago, with the derivation of embryonic stem cells from a human source in which I'd been involved. Kadimastem is preparing for its first clinical trial in ALS patients using embryonic stem cells. The scientific developments in Kadimastem insure that the application of these innovative technologies to cure additional incurable diseases of the nervous system and diabetes is near."

 

About Kadimastem

Kadimastem (www.kadimastem.com) is a biotechnology company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS, as well as diabetes. The company was founded in August 2009 by Professor Michel Revel and Yossi Ben Yosef, and is traded on the Tel Aviv Stock Exchange (TASE: KDST). The company's chairman is Dr. Eli Opper, formerly the Chief Scientist of the Israeli Ministry of Industry, Labor and Trade. The company's investors, in addition to the founders, include Altshuler Shaham Investment House, foreign investors (Julien Ruggieri and Avi Meizler), and additional institutional investors.

Kadimastem was founded based on patent protected technology that was developed at the Weizmann Institute of Science. Based on the company's unique platform, Kadimastem is developing two types of medical applications: A. Regenerative medicine, which repairs and replaces organs and tissue by using functioning cells differentiated from stem cells. The company focuses on transplanting healthy brain cells to support the survivability of nerve cells as cell therapy for ALS, and transplanting insulin-secreting pancreatic cells for the treatment of insulin-dependent diabetes; B. Drug screening platforms, which use functional human cells and tissues to discover new medicinal drugs. The company has two collaboration agreements with leading global pharmaceutical companies.

Kadimastem has an extensive scientific advisory board, featuring prominent scientists and pioneers: in the embryonic stem cells field, Professor Benjamin Reubinoff, Director of the Hadassah Human Embryonic Stem Cell Research Center and Senior Physician at the Department of Obstetrics and Gynecology at the Hadassah University Medical Center; Professor Joseph Itskovich, world renowned expert and pioneer in pluripotent stem cell research and former head of Obstetrics and Gynecology at RAMBAM Medical Center; in the neurodegenerative disease field, Professor Tamir Ben-Hur, Head of the Department of Obstetrics and Gynecology at Hadassah University Medical Center; and in the diabetes field, Professor Shimon Efrat, professor of Human Molecular Genetics and Juvenile Diabetes at Tel Aviv University and a world renowned expert in cell replacement therapy for diabetes and Professor Eddy Karnieli, former Director of the Institute for Endocrinology, Diabetes and Metabolism at the RAMBAM Medical Center, and a world renowned expert in these fields.


Press Releases Archive